Shield Therapeutics Balance Sheet Health
Financial Health criteria checks 3/6
Shield Therapeutics has a total shareholder equity of $27.1M and total debt of $5.7M, which brings its debt-to-equity ratio to 21.1%. Its total assets and total liabilities are $41.7M and $14.6M respectively.
Key information
21.1%
Debt to equity ratio
US$5.71m
Debt
Interest coverage ratio | n/a |
Cash | US$13.59m |
Equity | US$27.10m |
Total liabilities | US$14.57m |
Total assets | US$41.67m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: SHIE.F's short term assets ($26.1M) exceed its short term liabilities ($8.9M).
Long Term Liabilities: SHIE.F's short term assets ($26.1M) exceed its long term liabilities ($5.7M).
Debt to Equity History and Analysis
Debt Level: SHIE.F has more cash than its total debt.
Reducing Debt: SHIE.F's debt to equity ratio has increased from 0% to 21.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if SHIE.F has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if SHIE.F has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.